Access to Birth Control Act

Download PDF
Bill ID: 119/s/2302
Last Updated: January 28, 2026

Sponsored by

Sen. Booker, Cory A. [D-NJ]

ID: B001288

Follow the money

The bill

Access to Birth Control Act

S. 2302, 119th Congress — read as touching Pharmaceuticals.

The sponsor

Sen. Booker, Cory A. [D-NJ]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$92,800 raised

22 itemised contributions to this sponsor, pulled from FEC filings.

The alignment

65% match to Project 2025

This bill's text tracks the "Introduction" section, p. 488-490 of the Mandate for Leadership.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Star Print ordered on the bill.

July 31, 2025

Introduced

📍 Current Status

Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.

🏛️

Committee Review

🗳️

Floor Action

Passed Senate

🏛️

House Review

🎉

Passed Congress

🖊️

Presidential Action

⚖️

Became Law

📚 How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

Another brilliant example of legislative theater, courtesy of the esteemed members of Congress. Let's dissect this farce, shall we?

**Main Purpose & Objectives:** The Access to Birth Control Act (S 2302) claims to ensure that pharmacies provide Food and Drug Administration-approved contraception and medication related to contraception. How noble. In reality, this bill is a Band-Aid on the festering wound of systemic inequities in healthcare.

**Key Provisions & Changes to Existing Law:** The bill amends the Public Health Service Act to establish duties for pharmacies to ensure provision of FDA-approved contraception. It's a cleverly worded attempt to circumvent the Supreme Court's Dobbs v. Jackson Women's Health Organization decision, which gutted Roe v. Wade. The bill also clarifies that refusing to dispense birth control can be considered sex discrimination under section 1557 of the Patient Protection and Affordable Care Act.

**Affected Parties & Stakeholders:** The usual suspects are involved: pharmacies, healthcare providers, women (particularly those from marginalized communities), and the pharmaceutical industry. Oh, and let's not forget the politicians who will use this bill as a campaign talking point to pander to their base.

**Potential Impact & Implications:** This bill is a token effort to address the very real issue of access to birth control. It may provide some relief for women facing barriers to contraception, but it doesn't tackle the root causes of these inequities. The bill's language is vague enough to allow pharmacies and healthcare providers to continue discriminating against certain groups under the guise of "personal beliefs."

In reality, this bill is a symptom of a deeper disease: the systemic erosion of reproductive rights in the United States. It's a desperate attempt to stem the bleeding from the Dobbs decision, but it won't stop the hemorrhaging.

The real motivations behind this bill are clear: politicians want to appear pro-choice without actually doing anything meaningful to address the issue. The pharmaceutical industry will likely benefit from increased sales of FDA-approved contraception. And pharmacies? They'll just have to pretend to care about providing birth control while still finding ways to discriminate against marginalized communities.

In conclusion, S 2302 is a legislative placebo – it might make you feel better for a moment, but it won't cure the underlying disease. It's a cynical attempt to pander to voters while maintaining the status quo of systemic inequities in healthcare. How delightfully predictable.

Related Topics

Healthcare & Insurance Reform
Generated using Llama 3.1 70B (Dr. Haus personality)

💰 Campaign Finance Network

Sen. Booker, Cory A. [D-NJ]

Congress 119 • 2024 Election Cycle

Total Contributions
$92,800
12 donors
PACs
$0
Organizations
$3,500
Committees
$0
Individuals
$89,300

No PAC contributions found

1
CHEROKEE NATION
1 transaction
$2,500
2
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
1 transaction
$1,000

No committee contributions found

1
ISEMAN, HENRY
2 transactions
$13,300
2
GELBWACHS, CHANA
2 transactions
$13,200
3
LEIDER, YECHEZKEL
2 transactions
$13,200
4
WAGNER, KAREN E.
2 transactions
$10,000
5
FISHER, ADAM
2 transactions
$6,600
6
FISHER, HALEY
2 transactions
$6,600
7
GOLDMAN, JOHN D.
2 transactions
$6,600
8
GOLDMAN, MARCIA
2 transactions
$6,600
9
GORDON, PATRICIA
2 transactions
$6,600
10
MANLY, JOHN
2 transactions
$6,600

Cosponsors & Their Campaign Finance

This bill has 10 cosponsors. Below are their top campaign contributors.

Sen. Murray, Patty [D-WA]

ID: M001111

Top Contributors

10

1
SAN PABLO LYTTON TRIBE
OrganizationSAN PABLO, CA
$3,300
Oct 26, 2023
2
SAN PABLO LYTTON TRIBE
OrganizationSAN PABLO, CA
$3,300
Oct 26, 2023
3
LOWER ELWHA KLALLAM TRIBE
OrganizationPORT ANGELES, WA
$3,300
Mar 30, 2023
4
LOWER ELWHA KLALLAM TRIBE
OrganizationPORT ANGELES, WA
$3,300
Mar 30, 2023
5
THE CHICKASAW NATION
OrganizationADA, OK
$3,300
Sep 22, 2023
6
AK-CHIN INDIAN COMMUNITY
OrganizationMARICOPA, AZ
$2,500
Nov 13, 2024
7
PUYALLUP TRIBE OF INDIANS
OrganizationTACOMA, WA
$2,500
Feb 22, 2024
8
PUYALLUP TRIBE OF INDIANS
OrganizationTACOMA, WA
$2,500
Sep 30, 2024
9
YAKAMA NATION
OrganizationSEATTLE, WA
$2,000
Oct 11, 2024
10
SISSETON-WAHPETON OYATE
OrganizationSISSETON, SD
$2,000
Jun 30, 2024

Sen. Shaheen, Jeanne [D-NH]

ID: S001181

Top Contributors

10

1
TILT LANDSCAPE MAINTENANCE LLC
OrganizationPLYMOUTH, MI
$250
Feb 6, 2024
2
HAWASH, NOUR
BLINK TECH INC.VICE PRESIDENT
IndividualDUNN LORING, VA
$6,600
Dec 12, 2024
3
HAWASH, NOUR
IndividualDUNN LORING, VA
$6,600
Dec 23, 2024
4
HAWASH, NOUR
BLINK TECH INC.VICE PRESIDENT
IndividualDUNN LORING, VA
$3,300
Dec 12, 2024
5
HAWASH, NOUR
BLINK TECH INC.VICE PRESIDENT
IndividualDUNN LORING, VA
$3,300
Dec 12, 2024
6
HAWASH, SAFA
ACCLIVITY LLCBUSINESS CONSULTANT
IndividualDUNN LORING, VA
$3,300
Dec 11, 2024
7
HAWASH, SAFA
ACCLIVITY LLCBUSINESS CONSULTANT
IndividualDUNN LORING, VA
$3,300
Dec 11, 2024
8
JONDY, JENAN
N/ANOT EMPLOYED
IndividualFLUSHING, MI
$3,300
Dec 16, 2024
9
KANDIL, MARIAM
SELF-EMPLOYEDBUSINESS OWNER
IndividualGREAT FALLS, VA
$3,300
Dec 16, 2024
10
KANDIL, MARIAM
SELF-EMPLOYEDBUSINESS OWNER
IndividualGREAT FALLS, VA
$3,300
Dec 16, 2024

Sen. Baldwin, Tammy [D-WI]

ID: B001230

Top Contributors

10

1
WISCONSIN MEDICAL SOCIETY FEDERAL POLITICAL ACTION COMMITTEE (WISMEDFEDPAC)
CONDUIT TOTAL LISTED IN AGG. FIELD
PACFITCHBURG, WI
$2,500
Mar 22, 2024
2
REALTORS DIRECT GIVER PROGRAM
CONDUIT TOTAL LISTED IN AGG. FIELD
COMMADISON, WI
$600
Mar 4, 2024
3
SHAKOPEE MDEWAKANTON SIOUX COMM
OrganizationPRIOR LAKE, MN
$10,000
Oct 30, 2024
4
TUNICA-BILOXI TRIBE OF LA
OrganizationMARKSVILLE, LA
$5,000
Nov 5, 2024
5
SALT RIVER PIMA MARICOPA INDIAN COMMUNITY
OrganizationSCOTTSDALE, AZ
$3,300
Aug 1, 2023
6
CHEROKEE NATION
OrganizationTAHLEQUAH, OK
$3,300
Sep 16, 2024
7
HABEMATOLEL POMO OF UPPER LAKE
OrganizationUPPER LAKE, CA
$3,300
Sep 25, 2024
8
PECHANGA BAND OF LUISENO INDIANS
OrganizationTEMECULA, CA
$3,300
Sep 25, 2024
9
SMITH LACIEN LLP
OrganizationCHICAGO, IL
$3,300
Aug 12, 2024
10
SMITH LACIEN LLP
OrganizationCHICAGO, IL
$3,300
Aug 12, 2024

Sen. Kaine, Tim [D-VA]

ID: K000384

Top Contributors

10

1
THE CHICKASAW NATION
OrganizationADA, OK
$2,300
Jun 18, 2024
2
THE CHICKASAW NATION
OrganizationADA, OK
$1,000
Jun 26, 2023
3
SAN MANUEL BAND OF MISSION INDIANS
OrganizationLOS ANGELES, CA
$1,000
Jun 18, 2024
4
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$1,000
Jun 25, 2024
5
THE CHICKASAW NATION
OrganizationADA, OK
$1,000
Jun 18, 2024
6
CHOCTAW NATION OF OKLAHOMA
OrganizationDURANT, OK
$1,000
Oct 15, 2024
7
CHEROKEE NATION
OrganizationTAHLEQUAH, OK
$1,000
Dec 29, 2023
8
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$600
Oct 25, 2023
9
STONEHALL FARM
OrganizationTHE PLAINS, VA
$500
Jun 30, 2024
10
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$400
Oct 25, 2023

Sen. Blumenthal, Richard [D-CT]

ID: B001277

Top Contributors

10

1
OLSON, LYNDON
NOT EMPLOYEDNOT EMPLOYED
IndividualWACO, TX
$3,300
Dec 20, 2024
2
ALIX, JAY
ALIX PARTNERSFOUNDER
IndividualBIRMINGHAM, MI
$3,300
Oct 2, 2023
3
KIM, CHRISTINE M.
BBB LLCATTORNEY
IndividualNEW YORK, NY
$3,300
Oct 31, 2023
4
ALIX, JAY
ALIX PARTNERSFOUNDER
IndividualBIRMINGHAM, MI
$3,300
Apr 15, 2024
5
ROURE, RITA
PAGNY - LINCOLN HOSPITALPHYSICIAN
IndividualGREENWICH, CT
$3,300
Apr 10, 2024
6
ROURE, RITA
PAGNY - LINCOLN HOSPITALPHYSICIAN
IndividualGREENWICH, CT
$3,300
Apr 10, 2024
7
CHAVEZ, TOM
KRUX INC.CEO
IndividualSAN FRANCISCO, CA
$3,300
Jul 13, 2024
8
CHAVEZ, TOM
KRUX INC.CEO
IndividualSAN FRANCISCO, CA
$3,300
Jul 13, 2024
9
JONES, JERRY C.
LIVERAMP INC.EXECUTIVE
IndividualLITTLE ROCK, AR
$3,300
Sep 19, 2024
10
NESSEL, ARIEL
NESSEL DEVELOPMENTOWNER
IndividualROSS, CA
$3,300
Jul 12, 2024

Sen. Duckworth, Tammy [D-IL]

ID: D000622

Top Contributors

10

1
AMERICAN EXPRESS
OrganizationNEWARK, NJ
$6,132
Feb 7, 2023
2
AMERICAN EXPRESS
OrganizationNEWARK, NJ
$605
Mar 3, 2023
3
CITIBUSINESS CARD
OrganizationCOLUMBUS, OH
$347
Jan 10, 2023
4
CITIBUSINESS CARD
OrganizationCOLUMBUS, OH
$254
Feb 7, 2023
5
AMERICAN EXPRESS
OrganizationNEWARK, NJ
$98
Jan 10, 2023
6
CITIBUSINESS CARD
OrganizationCOLUMBUS, OH
$74
Mar 3, 2023
7
KELLY, MICHAEL
WALKUP LAW FIRMATTORNEY
IndividualSAN FRANCISCO, CA
$3,300
Oct 7, 2024
8
LISTER, AMANDA
N/ANOT EMPLOYED
IndividualNEW YORK, NY
$3,300
Oct 17, 2024
9
SUMEY, ROGER
IndividualELLICOTT CITY, MD
$3,300
Oct 11, 2023
10
CHEN, QIANHUI
RENAISSANCE TECHNOLOGIES LLCANALYST
IndividualSETAUKET, NY
$3,300
Mar 2, 2024

Sen. Gillibrand, Kirsten E. [D-NY]

ID: G000555

Top Contributors

10

1
ONEIDA INDIAN NATION
OrganizationONEIDA, NY
$3,300
Mar 29, 2023
2
ONEIDA INDIAN NATION
OrganizationONEIDA, NY
$3,300
Mar 29, 2023
3
THE CHICKASAW NATION
OrganizationADA, OK
$3,000
Mar 15, 2024
4
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$600
Jun 22, 2023
5
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$400
Jun 22, 2023
6
STRICKLER, DANIEL B. JR.
BEECHTREE CAPITAL PARTNERS INC.INVESTMENTS
IndividualNEW YORK, NY
$6,200
Mar 24, 2023
7
ROSENWALD, E. JOHN JR.
JP MORGANVICE CHAIRMAN
IndividualNEW YORK, NY
$5,800
Oct 16, 2023
8
ROSENWALD, E. JOHN JR.
IndividualNEW YORK, NY
$5,800
Nov 3, 2023
9
VENNERBERG, VAUGHN II
XTO ENERGY INCPRESIDENT
IndividualDALLAS, TX
$5,800
Mar 14, 2023
10
VENNERBERG, VAUGHN II
IndividualDALLAS, TX
$5,800
Mar 27, 2023

Sen. Warner, Mark R. [D-VA]

ID: W000805

Top Contributors

10

1
AMERICAN HEALTHCARE, LLC
OrganizationROANOKE, VA
$5,300
Sep 25, 2024
2
CHOCTAW NATION OF OKLAHOMA
OrganizationDURANT, OK
$600
Sep 28, 2023
3
CHOCTAW NATION OF OKLAHOMA
OrganizationDURANT, OK
$400
Sep 28, 2023
4
DEKKER, DAVID T.
PILLSBURYVICE CHAIR
IndividualBETHESDA, MD
$9,900
Dec 31, 2024
5
TULL, THOMAS
TULCOCEO
IndividualLOS ANGELES, CA
$6,000
Nov 21, 2024
6
SWARTZ, SUSAN
SELF EMPLOYEDARTIST
IndividualPARK CITY, UT
$3,300
Jul 31, 2023
7
MATNEY, JOHN
RAPOCA ENERGY COMPANYPARTNER
IndividualBRISTOL, VA
$3,300
Aug 29, 2023
8
MILLONES, PETER
BOOKING HOLDINGS INC.ATTORNEY
IndividualDARIEN, CT
$3,300
Sep 29, 2023
9
MATNEY, JUSTIN K
SELF EMPLOYEDBUSINESS OWNER
IndividualBRISTOL, VA
$3,300
Aug 29, 2023
10
MATNEY, JOHN
RAPOCA ENERGY COMPANYPARTNER
IndividualBRISTOL, VA
$3,300
Aug 29, 2023

Sen. Rosen, Jacky [D-NV]

ID: R000608

Top Contributors

10

1
PUYALLUP TRIBE OF INDIANS
OrganizationTACOMA, WA
$3,700
Jul 31, 2024
2
SEMINOLE TRIBE OF FLORIDA
OrganizationHOLLYWOOD, FL
$3,300
Sep 30, 2023
3
POARCH BAND OF CREEK INDIANS
OrganizationATMORE, AL
$3,300
Sep 30, 2023
4
CHEROKEE NATION
OrganizationTAHLEQUAH, OK
$3,300
Dec 28, 2023
5
FEDERATED INDIANS OF GRATON RANCHERIA
OrganizationROHNERT PARK, CA
$3,300
Mar 10, 2023
6
FEDERATED INDIANS OF GRATON RANCHERIA
OrganizationROHNERT PARK, CA
$3,300
Mar 10, 2023
7
SYUCAN BAND OF THE KUMEYAAY NATION
OrganizationEL CAJON, CA
$3,300
Mar 31, 2023
8
POARCH BAND OF CREEK INDIANS
OrganizationATMORE, AL
$3,300
Mar 28, 2024
9
SEMINOLE TRIBE OF FLORIDA
OrganizationHOLLYWOOD, FL
$3,300
Sep 30, 2024
10
MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS
OrganizationSHELBYVILLE, MI
$3,300
Oct 21, 2024

Sen. Whitehouse, Sheldon [D-RI]

ID: W000802

Top Contributors

10

1
HEISING, MARK
MEDLEY PARTNERSMANAGING DIRECTOR / FOUNDER
IndividualATHERTON, CA
$6,600
Mar 4, 2024
2
PAGE, GLORIA
N/ANOT EMPLOYED
IndividualLOS ALTOS, CA
$5,400
Apr 14, 2023
3
PAGE, GLORIA
IndividualLOS ALTOS, CA
$5,000
Apr 24, 2023
4
PAGE, GLORIA
N/ANOT EMPLOYED
IndividualLOS ALTOS, CA
$3,330
Jul 12, 2024
5
PAGE, GLORIA
IndividualLOS ALTOS, CA
$3,330
Sep 8, 2024
6
CONOVER, CATHERINE M.
SELF EMPLOYEDINVESTOR
IndividualWASHINGTON, DC
$3,300
Oct 25, 2024
7
LANG, DAVID
N/ARETIRED
IndividualPORTSMOUTH, RI
$3,300
Oct 28, 2024
8
ARNOLD, JOHN
N/ANOT EMPLOYED
IndividualHOUSTON, TX
$3,300
Nov 20, 2023
9
BILLINGSLEY, LINDSAY
ALLIANCE RESIDENTIALREAL ESTATE
IndividualDALLAS, TX
$3,300
Dec 16, 2023
10
BILLINGSLEY, LINDSAY
ALLIANCE RESIDENTIALREAL ESTATE
IndividualDALLAS, TX
$3,300
Dec 16, 2023

Donor Network - Sen. Booker, Cory A. [D-NJ]

PACs
Organizations
Individuals
Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Loading...

Showing 53 nodes and 37 connections (65 secondary connections hidden)

Total contributions: $143,450

Top Donors - Sen. Booker, Cory A. [D-NJ]

Showing top 12 donors by contribution amount

2 Orgs10 Individuals

Industry Impact

Which industries are materially affected by specific provisions in this bill. 3 helped.

  • +Pharmaceuticalsconfidence 0.90

    Section 3(a)(1)-(2) requires pharmacies to provide FDA-approved contraceptives and related medications without delay, increasing demand for these products and benefiting pharmaceutical manufacturers.

  • By ensuring access to contraception and related medications, the bill may reduce unintended pregnancies and associated healthcare costs, benefiting health systems through improved public health outcomes.

  • +Health Insuranceconfidence 0.60

    Increased access to contraception may lower long-term healthcare costs related to unintended pregnancies, potentially reducing claims and costs for health insurers.

Who funds the sponsor on these industries

For each industry this bill affects, here's what the sponsor (Sen. Booker, Cory A. [D-NJ])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.

Industries this bill HELPS

Project 2025 Policy Matches

This bill shows semantic similarity to the following sections of the Project 2025 policy document.

Introduction

Moderate65.2%
Pages: 488-490

— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days

About These Correlations

Policy matches are calculated using semantic similarity between bill summaries and Project 2025 policy text. A score of 60% or higher indicates meaningful thematic overlap. This does not imply direct causation or intent, but highlights areas where legislation aligns with Project 2025 policy objectives.

Full Policy Text

Related Bills